Isoginkgetin

Isoginkgetin is a pre-mRNA splicing inhibitor inhibitor. Isoginkgetin also inhibits activities of both Akt, NF-κB and MMP-9. Isoginkgetin inhibits the activity of the 20S proteasome, induces apoptosis and activates autophagy[1][2].

Product Specifications

CAS Number

[548-19-6]

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

Akt; Apoptosis; Autophagy; MMP; NF-κB; Proteasome

Type

Natural Products

Related Pathways

Apoptosis; Autophagy; Metabolic Enzyme/Protease; NF-κB; PI3K/Akt/mTOR

Applications

Cancer-Kinase/protease

Field of Research

Cancer; Inflammation/Immunology

Assay Protocol

https://www.medchemexpress.com/Isoginkgetin.html

Purity

99.95

Solubility

DMSO : 100 mg/mL (ultrasonic; warming; heat to 60°C)

Smiles

O=C1C=C(C2=CC=C(OC)C=C2)OC3=C(C4=CC(C5=CC(C6=C(O)C=C(O)C=C6O5)=O)=CC=C4OC)C(O)=CC(O)=C13

Molecular Formula

C32H22O10

Molecular Weight

566.51

Precautions

H302, H315, H319, H335

References & Citations

[1]Yoon SO, et al. Isoginkgetin inhibits tumor cell invasion by regulating phosphatidylinositol 3-kinase/Akt-dependent matrix metalloproteinase-9 expression. Mol Cancer Ther. 2006 Nov;5 (11) :2666-75. |[2]Tsalikis J, et al. Isoginkgetin, a Natural Biflavonoid Proteasome Inhibitor, Sensitizes Cancer Cells to Apoptosis via Disruption of Lysosomal Homeostasis and Impaired Protein Clearance. Mol Cell Biol. 2019 Apr 30;39 (10) :e00489-18.|[3]Li P, et al. Isoginkgetin treatment attenuated lipopolysaccharide-induced monoamine neurotransmitter deficiency and depression-like behaviors through downregulating p38/NF-κB signaling pathway and suppressing microglia-induced apoptosis. J Psychopharmacol. 2021 Oct;35 (10) :1285-1299.